MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwired - Jun 27, 2013) - MorphoSys AG /
MorphoSys AG : MorphoSys to Host Conference Call on Strategic Alliance with
Celgene to Advance CD38 Cancer Program MOR202 for Patients with Multiple
Myeloma. Ad hoc announcement according to § 15 WpHG. Processed and
transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
On June 26, 2013, MorphoSys and Celgene Corporation announced an agreement
to jointly develop MOR202 globally and to co-promote MOR202 in Europe.
MOR202 is a fully human monoclonal antibody targeting CD38 to treat
patients with multiple myeloma (MM) and certain leukemias.
Today at 4:00 p.m. CET (10:00am EST, 03:00pm BST), the Management Board of
MorphoSys AG will host a public conference call and webcast to present more
information on the transaction.
Dial-in number for the Conference Call (listen-only):
Germany: +49 89 2444 32975
For U.K. residents: +44 20 3003 2666
For U.S. residents: +1 202 204 1514
MorphoSys offers participants the opportunity to follow the presentation
through a simultaneous slide presentation online at
An audio replay and manuscripts of the conference will be
available on www.morphosys.com/conference-calls in due course.
MorphoSys developed HuCAL, the most successful antibody library technology
in the pharmaceutical industry. By successfully applying this and other
patented technologies, MorphoSys has become a leader in the field of
therapeutic antibodies, one of the fastest-growing drug classes in human
healthcare. Together with its pharmaceutical partners, MorphoSys has built
a therapeutic pipeline of more than 70 human antibody drug candidates for
the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to
name just a few. With its ongoing commitment to new antibody technology and
drug development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys, visit
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
RapMAT®, arYla®, Ylanthia® and 100 billion high
potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology
GmbH, a subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements
concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of the
date of this release and involve risks and uncertainties. Should actual
conditions differ from the Company's assumptions, actual results and
actions may differ from those anticipated. MorphoSys does not intend to
update any of these forward-looking statements as far as the wording of
the relevant press release is concerned.
Conference Call Alert (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE